STUDY OF THE LONG-TERM EFFECTS OF DIABETES ON THE OVERALL HEALTH AND QUALITY OF LIFE IN THALASSEMIA PATIENTS
Downloads
Thalassemia is a genetic blood disorder characterized by chronic anemia, requiring regular blood transfusions and chelation therapy. Diabetes mellitus is a common complication in thalassemia patients, primarily due to iron overload affecting the pancreas. This study investigates the long-term effects of diabetes on the overall health and quality of life in thalassemia patients. The research aims to understand how diabetes exacerbates complications associated with thalassemia and to identify strategies for improved management and care. The study includes a cohort of thalassemia patients with diabetes, compared to a control group of thalassemia patients without diabetes. Parameters assessed include glycemic control, incidence of diabetes-related complications, and overall health markers such as liver function, cardiovascular health, and renal function. Quality of life is measured using standardized questionnaires addressing physical, emotional, and social well-being. Preliminary findings indicate that thalassemia patients with diabetes have a significantly higher incidence of comorbid conditions, including cardiovascular disease and renal impairment (De Sanctis et al., 2016). Additionally, the quality of life in these patients is notably lower, with increased reports of fatigue, pain, and psychological distress (Haines et al., 2013). Effective management of diabetes in thalassemia patients, through regular monitoring and tailored treatment plans, is crucial in mitigating these adverse effects and improving patient outcomes (Farmaki et al., 2006). This study underscores the importance of integrated care approaches for thalassemia patients with diabetes, emphasizing the need for multidisciplinary teams to address the complex interplay of these conditions. Further research is needed to develop targeted interventions that can enhance the long-term health and quality of life for this vulnerable patient population. Results: study indicated that plant extracts exhibited higher inhibition than antibiotics. The minimum inhibitory concentration (MIC) while the results of the lowest inhibitory concentration of carvacrol for the bacterial species under study showed that it had an effect at a concentration of 615 µg/ml against Escherichia coli, 307.5 µg/ml for the species Corynebacterium stratium, Morganella morganii and Pseudomonas aeruginosa, and the least effect was 76.875 µg/ml on Staphylococcus aureus, it gave less results than the antibiotic used Carvacrol (Absorbance was measured at Wavelength 600) .
. Ang, A. L., Koay, E. S., Ng, I., Linn, Y. C., Goh, Y. T., & Tan, L. K. (2010). Diabetes mellitus in transfusion dependent thalassemia major patients. Journal of Pediatric Endocrinology and Metabolism, 23(5), 497-502. https://doi.org/10.1515/JPEM.2010.23.5.497
. Arora, M., Chandra, J., Singh, V., Suri, J. C., & Narayan, S. (2011). Insulin resistance and β-cell function in thalassemia major. Journal of Pediatric Endocrinology and Metabolism, 24(3-4), 221-224. https://doi.org/10.1515/JPEM.2011.024
. Borgna-Pignatti, C., Cappellini, M. D., De Stefano, P., Del Vecchio, G. C., Forni, G. L., Gamberini, M. R., & Piga, A. (2004). Survival and complications in thalassemia. Annals of the New York Academy of Sciences, 1054(1), 40-47. https://doi.org/10.1196/annals.1345.006
. Cappellini, M. D., Cohen, A., Eleftheriou, A., Piga, A., Porter, J., & Taher, A. (2005). Guidelines for the clinical management of thalassemia. Thalassemia International Federation.
. De Sanctis, V., Soliman, A. T., Daar, S., Di Maio, S., Elsedfy, H., Fiscina, B., & Kattamis, C. (2016). Diabetes and glucose metabolism in thalassemia major: An update. Mediterranean Journal of Hematology and Infectious Diseases, 8(1), e2016054. https://doi.org/10.4084/MJHID.2016.054
. Farmaki, K., Angelopoulos, N., Anagnostopoulos, G., Zoumbos, N., & Kattamis, C. (2006). Effect of combined therapy with deferiprone and desferrioxamine on glucose metabolism in patients with thalassemia major. British Journal of Haematology, 134(4), 438-444. https://doi.org/10.1111/j.1365-2141.2006.06223.x
. Haines, C. A., Rollinson, V., Hilliard, L. M., & Mudge, D. W. (2013). Quality of life of people with diabetes and thalassemia: Findings from a pilot study. International Journal of Hematology, 98(4), 464-470. https://doi.org/10.1007/s12185-013-1447-4
. Harmatz, P., Butensky, E., Quirolo, K., Williams, R., Ferrell, L., Moyer, T., & Neumayr, L. (2000). Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood, 96(1), 76-79.
. Karami, H., Kosaryan, M., Roshan, P., & Dorgalaleh, A. (2013). Insulin resistance and β-cell function in patients with β-thalassemia major. International Journal of Hematology-Oncology and Stem Cell Research, 7(3), 14-20.
. Katz, K., Weintraub, M., Zaizov, R., & Rachmilewitz, E. A. (2005). Endocrine function in thalassemia major. Archives of Disease in Childhood, 60(8), 736-741. https://doi.org/10.1136/adc.60.8.736
. Lakhkar, B. B., & Reddy, K. S. (2010). Effect of diabetes mellitus on pulmonary functions in patients with β-thalassemia major. International Journal of Diabetes in Developing Countries, 30(4), 214-217. https://doi.org/10.4103/0973-3930.70877
. Lukens, J. N. (1999). The thalassemias and related disorders. In J. W. Lichtman, M. A. Beutler, & T. J. Kipps (Eds.), Williams hematology (6th ed., pp. 490-521). McGraw-Hill.
. Modell, B., Khan, M., & Darlison, M. (2000). Survival in β-thalassemia major in the UK: Data from the UK Thalassemia Register. The Lancet, 355(9220), 2051-2052. https://doi.org/10.1016/S0140-6736(00)02357-6
. Moirand, R., Mortaji, A. M., Loreal, O., Paillard, F., Brissot, P., & Deugnier, Y. (1997). A new syndrome of liver iron overload with normal transferrin saturation. The Lancet, 349(9045), 95-97. https://doi.org/10.1016/S0140-6736(96)06393-9
. Noetzli, L. J., Carson, S. M., Nord, A. S., Coates, T. D., & Wood, J. C. (2008). Longitudinal analysis of heart and liver iron in thalassemia major. Blood, 112(7), 2973-2978. https://doi.org/10.1182/blood-2008-03-147124
. Olivieri, N. F., & Brittenham, G. M. (1997). Iron-chelating therapy and the treatment of thalassemia. Blood, 89(3), 739-761.
. Origa, R., Fiumana, E., Gamberini, M. R., Armari, G., Loreti, A., Neri, M. G., & Piga, A. (2007). Iron overload in thalassemia: New insights for an old enemy. Hematology Journal, 92(4), 611-612.
. Porter, J. B., & Davis, B. A. (2002). Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassemia. Blood Reviews, 16(1), 61-66. https://doi.org/10.1054/blre.2001.0182
. Rund, D., & Rachmilewitz, E. (2005). β-thalassemia. New England Journal of Medicine, 353(11), 1135-1146. https://doi.org/10.1056/NEJMra050436
. Sharifi, Z., & Zarei, T. (2007). Prevalence of diabetes and impaired glucose tolerance in beta-thalassemia major patients. Iranian Journal of Blood and Cancer, 3(1), 24-28.
. Soliman, A. T., Yassin, M., El-Awwa, A., Osman, M., & de Sanctis, V. (2013). Chronic anemia and thyroid function. Acta Bio-Medica: Atenei Parmensis, 84(1), 72-78.
. Telfer, P. T., Prestcott, E., Holden, S., Walker, M., Stevens, D., & Wonke, B. (2000). Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassemia major. British Journal of Haematology, 110(4), 971-977. https://doi.org/10.1046/j.1365-2141.2000.02294.x
. Tzoulis, P., & Kassi, E. (2014). Endocrine consequences of thalassemia: New insights. Pediatric Endocrinology Reviews, 11(3), 277-286.
. Vogiatzi, M. G., Macklin, E. A., Trachtenberg, F. L., Fung, E. B., Cheung, A. M., Vichinsky, E., & Giardina, P. J. (2009). Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassemia syndromes in North America. British Journal of Haematology, 146(5), 546-556. https://doi.org/10.1111/j.1365-2141.2009.07787.x
. Wu, H. P., Lin, C. L., Chang, Y. C., Liu, C. L., & Jiang, W. J. (2003). Survival and complications of thalassemia major patients in northern Taiwan. Pediatric Blood & Cancer, 41(6), 1108-1111. https://doi.org/10.1002/pbc.10491
Copyright (c) 2024 Abdulhameed Rashid Hameed ahmed, Rasha Ahmed Abdullah, Maha Saddam wasmi, Rawaa Abd Alkareem Alush, Ammar Abbass Mehsun
This work is licensed under a Creative Commons Attribution 4.0 International License.
